<p>Researchers at the University of Colorado Anschutz Cancer Center have identified a previously unknown metabolic weakness in the stem cells that drive high-risk myelodysplastic syndromes (MDS), a discovery that could lead to more targeted treatments for this aggressive blood cancer.</p>